---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-22-000028"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:08:25.965605+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q2 2022 net loss $22.9M; cash $160.9M, runway into Q3 2024

## Summary
- Net loss of $22.9M in Q2 2022, narrowing from $34.4M in Q2 2021.
- Cash and investments $160.9M as of June 30, 2022; expected to fund ops into Q3 2024.
- First patient dosed in Phase 1 study of BDTX-1535; clinical update expected in 2023.
- Appointed Sergey Yurasov as Chief Medical Officer in June 2022.
- IND submission for BDTX-4933 targeted for H1 2023.

## SEC filing metadata
- accession: 0001701541-22-000028
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000028/0001701541-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000028/bdtx-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-22-000028
- JSON: https://secwatch.observer/filing/0001701541-22-000028.json
- Plain text: https://secwatch.observer/filing/0001701541-22-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.